JP2024522371A5 - - Google Patents
Info
- Publication number
- JP2024522371A5 JP2024522371A5 JP2023575819A JP2023575819A JP2024522371A5 JP 2024522371 A5 JP2024522371 A5 JP 2024522371A5 JP 2023575819 A JP2023575819 A JP 2023575819A JP 2023575819 A JP2023575819 A JP 2023575819A JP 2024522371 A5 JP2024522371 A5 JP 2024522371A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence described
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209915P | 2021-06-11 | 2021-06-11 | |
| US63/209,915 | 2021-06-11 | ||
| PCT/US2022/032944 WO2022261395A1 (en) | 2021-06-11 | 2022-06-10 | Anti-upar antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522371A JP2024522371A (ja) | 2024-06-18 |
| JP2024522371A5 true JP2024522371A5 (enExample) | 2025-06-18 |
Family
ID=84425501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575819A Pending JP2024522371A (ja) | 2021-06-11 | 2022-06-10 | 抗ｕＰＡＲ抗体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240254253A1 (enExample) |
| EP (1) | EP4352106A4 (enExample) |
| JP (1) | JP2024522371A (enExample) |
| CN (1) | CN117769569A (enExample) |
| AU (1) | AU2022289491A1 (enExample) |
| CA (1) | CA3221903A1 (enExample) |
| WO (1) | WO2022261395A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025006714A1 (en) * | 2023-06-29 | 2025-01-02 | Cold Spring Harbor Laboratory | Anti-upar car t cells and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813091A (en) * | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| AU2012293720A1 (en) * | 2011-08-05 | 2014-02-27 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Constitutively active uPAR variants and their use for the generation and isolation of inhibitory antibodies |
| WO2019113248A1 (en) * | 2017-12-07 | 2019-06-13 | The Regents Of The University Of California | Anti-upar antibody-drug conjugates and methods of use thereof |
| EP3902822A4 (en) * | 2018-12-27 | 2022-12-28 | Gigagen, Inc. | ANTI-PD-1 BINDING PROTEINS AND METHODS OF USE THEREOF |
| US20220098320A1 (en) * | 2019-02-01 | 2022-03-31 | Memorial Sloan Kettering Cancer Center | Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker |
| CA3131953A1 (en) * | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
-
2022
- 2022-06-10 EP EP22821080.3A patent/EP4352106A4/en active Pending
- 2022-06-10 AU AU2022289491A patent/AU2022289491A1/en active Pending
- 2022-06-10 WO PCT/US2022/032944 patent/WO2022261395A1/en not_active Ceased
- 2022-06-10 CA CA3221903A patent/CA3221903A1/en active Pending
- 2022-06-10 JP JP2023575819A patent/JP2024522371A/ja active Pending
- 2022-06-10 CN CN202280054177.2A patent/CN117769569A/zh active Pending
-
2023
- 2023-12-11 US US18/535,395 patent/US20240254253A1/en active Pending